癌症防控有了新突破（大健康观察）

Group 1 - The first domestic nine-valent HPV vaccine was administered in Fuyang, Anhui Province, on November 26, 2025, benefiting women aged 9 to 45 and promoting primary prevention of cervical cancer [2] - A recent conference in Beijing gathered experts from various cancer fields to discuss advancements in diagnosis and treatment, emphasizing the importance of clinical research innovation in improving patient outcomes [3][4] Group 2 - Significant progress has been made in the treatment of gastrointestinal tumors in China, with innovative drugs driving updates in authoritative treatment guidelines and new clinical research strategies emerging [4] - The treatment of urological tumors is evolving towards a combination of surgery and medication, with advancements in minimally invasive techniques and drug therapies improving patient outcomes [5] Group 3 - The treatment landscape for nasopharyngeal carcinoma is being optimized, with immunotherapy becoming a first-line option for advanced cases, significantly improving survival rates [6] - CAR-T cell therapy and targeted drugs are providing long-term survival opportunities for patients with hematological tumors, although challenges remain in early diagnosis and treatment accessibility [6] Group 4 - The industry is moving towards a new era of precision, individualized, and multidisciplinary collaboration in cancer treatment, with a consensus on the need to enhance diagnostic and treatment systems [7] - The "People's Good Doctor · Camellia Plan" aims to promote the translation of research findings into clinical practice and improve healthcare services for the public [8]